{"nctId":"NCT00488631","briefTitle":"An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","startDateStruct":{"date":"2007-09"},"conditions":["Colitis, Ulcerative"],"count":1228,"armGroups":[{"label":"Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo","Biological: Golimumab 100 mg"]},{"label":"GLM-I-Rsp-Golimumab 50 mg Maintenance","type":"EXPERIMENTAL","interventionNames":["Biological: Golimumab 50 mg","Biological: Golimumab 100 mg"]},{"label":"GLM-I-Rsp-Golimumab 100 mg Maintenance","type":"EXPERIMENTAL","interventionNames":["Biological: Golimumab 100 mg","Biological: Golimumab 200 mg"]},{"label":"Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo","Biological: Golimumab 100 mg"]},{"label":"PBO-I-nonRsp-Golimumab 100 mg Maintenance","type":"EXPERIMENTAL","interventionNames":["Biological: Golimumab 100 mg"]},{"label":"GLM-I-nonRsp-Golimumab 100 mg Maintenance","type":"EXPERIMENTAL","interventionNames":["Biological: Golimumab 100 mg"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Golimumab 50 mg","otherNames":[]},{"name":"Golimumab 100 mg","otherNames":[]},{"name":"Golimumab 200 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants who received all study agent administrations and completed the Week 6 Mayo score evaluation in induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)\n* Participants who completed the Week 0 visit for this maintenance study C0524T18 (NCT00488631) on the same day as the Week 6 visit of the induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)\n\nExclusion Criteria:\n\n* Participants who increased the dose of their concomitant (given at the same time) UC medications since Week 0 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)\n* Participants who initiated a concomitant UC medication since Week 0 of an induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)\n* Participants who had a partial or total colectomy (surgery to remove part or all of the colon) or an ostomy (surgical construction of an artificial opening (stoma) for external fistulization of a duct or vessel by insertion of a tube with or without a supportive stent) since Week 0 of an induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)\n* Participants with signs or symptoms of latent or active granulomatous infection (including TB); a nontuberculous mycobacterial infection or opportunistic infection; or infection with HIV (Human Immunodeficiency Virus), hepatitis B, or hepatitis C\n* Participants with signs and symptoms of any malignancy or suggestive of a possible lymphoproliferative disease (disorders characterized by proliferation of lymphoid tissue, general or unspecified)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants in Clinical Response Through Week 54","description":"Clinical response is defined as decrease from induction baseline in Mayo score by greater than or equal to (\\>=) 30 percent and \\>= 3, with either decrease from induction baseline in rectal bleeding subscore of \\>= 1 or rectal bleeding subscore of 0 or 1. Participants who lost clinical response prior to Week 54 were considered not to meet endpoint. Mayo score is sum of 4 subscores (ie, stool frequency, rectal bleeding, endoscopic findings, physician's global assessment); each rated on scale from 0 to 3, with higher scores indicating more severe disease. Total Mayo score value ranges from 0 to 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Remission at Both Week 30 and Week 54","description":"Clinical remission is defined as a Mayo score of less than or equal to 2, with no individual sub-score greater than 1. The Mayo score is sum of 4 sub-scores (i.e., stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total Mayo score value ranges from 0 to 12. The number of participants in clinical remission at both the weeks that is Week 30 as well as Week 54 will be reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Mucosal Healing at Both Week 30 and Week 54","description":"Mucosal healing is determined from the endoscopy sub-score of the Mayo score. Mucosal healing is defined as an endoscopy sub-score of 0 or 1. Higher score indicates higher severity of disease. Endoscopy sub-score ranges from 0 (normal or inactive disease) to 3 (severe disease; spontaneous bleeding and ulceration). The number of participants with mucosal healing at both the weeks that is Week 30 as well as Week 54 will be reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Remission at Both Week 30 and 54 Among Participants With Clinical Remission at Week 0 of Maintenance Study","description":"Clinical remission is defined as a Mayo score of less than or equal to 2, with no individual sub-score greater than 1. The Mayo score is sum of 4 sub-scores (i.e., stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total Mayo score value ranges from 0 to 12. The number of participants in clinical remission at both the weeks that is Week 30 as well as Week 54 will be reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Remission at Week 54 and Not Receiving Concomitant Corticosteroids Among Participants on Corticosteroids at Week 0 of Maintenance Study","description":"Clinical remission is defined as a Mayo score of less than or equal to 2, with no individual sub-score greater than 1. The Mayo score is sum of 4 sub-scores (i.e., stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total Mayo score value ranges from 0 to 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":156},"commonTop":["Colitis Ulcerative","Nasopharyngitis","Headache","Upper Respiratory Tract Infection","Arthralgia"]}}}